Prolia (Denosumab) Manufacturer Bridge Programs: How to Get Prolia Cheaper in 2026

What Is the Amgen Assist 360 Program for Prolia?

Amgen Assist 360 is Amgen's centralized patient-support hub that covers Prolia and several other Amgen biologics. The program exists because Prolia's list price sits near $1,400 per injection, and patients who receive it every six months face an annual drug cost approaching $2,800 before insurance. Amgen Assist 360 connects patients and prescribers to three distinct pathways: a commercial copay card, a free-drug program for uninsured patients, and reimbursement support for navigating payer denials.

Enrollment is handled by calling 1-888-762-6436 or by submitting a form at AmgenAssist360.com. Most prescribers' offices initiate enrollment on the patient's behalf at the time of the first prescription.

Why the Program Exists

Prolia is a RANK ligand inhibitor that reduces fracture risk in postmenopausal women with osteoporosis. The FREEDOM trial (N=7,868) showed that denosumab reduced new vertebral fracture risk by 68% and hip fracture risk by 40% over 36 months versus placebo (NEJM, 2009). Given that clinical outcome, missed doses due to cost carry real skeletal consequences. Stopping denosumab abruptly can trigger a rebound increase in bone resorption markers and, in some patients, multiple vertebral fractures within 18 months of discontinuation (Osteoporosis International, PubMed). Continuity matters. The bridge programs exist, in part, to prevent treatment gaps.

Who Administers It Day to Day

Amgen Assist 360 case managers handle incoming applications, verify insurance status, and route patients to the correct benefit. For commercial copay card applications, turnaround is typically same-day or next-day. For the Safety Net Foundation, review can take 5 to 10 business days. Prescribers can also designate their office as a "hub site," which allows staff to track patient enrollment status through a dedicated online portal.

The Amgen Commercial Copay Card: Details, Eligibility, and Limits

The commercial copay card (sometimes called the Prolia Co-Pay Program) targets patients who carry commercial or private health insurance. It is not available to patients enrolled in federal programs including Medicare Part B, Medicare Part D, Medicaid, TRICARE, or any other government-funded plan. That restriction is not arbitrary. Federal anti-kickback statutes prohibit manufacturer copay assistance for government-beneficiary patients (42 U.S.C. § 1320a-7b).

What the Card Actually Covers

Eligible patients may pay as little as $0 out of pocket per dose, subject to a per-year maximum benefit that Amgen adjusts periodically. For 2025 and projected into 2026, the annual cap has been approximately $10,000 in total copay support per calendar year. Because Prolia is dosed twice yearly, the practical effect for most commercially insured patients is that their net cost is $0 for both injections combined, as long as their insurer's allowed amount does not exceed the annual cap.

The card covers the drug cost only. It does not cover the administration fee charged by the physician's office or infusion center for the injection itself. That fee, typically $25 to $75, is billed separately and remains the patient's responsibility unless covered by insurance.

How to Activate the Card

1. The prescriber's office enrolls the patient through Amgen Assist 360 by phone or online.
2. Amgen verifies insurance eligibility in real time.
3. A copay card number or electronic benefit is issued and attached to the patient's chart.
4. At each dose visit, the office applies the card at billing rather than the patient presenting a physical card at a pharmacy (Prolia is a physician-administered drug, not a retail pharmacy product).

Income is not a qualifying criterion for the commercial copay card. Any commercially insured patient who is not a government-plan beneficiary may apply.

Amgen Safety Net Foundation: Free Drug for Uninsured and Underinsured Patients

The Amgen Safety Net Foundation (ASNF) is a separate 501(c)(3) charitable foundation that provides Prolia at no cost to patients who meet financial need criteria and lack adequate insurance coverage. It is the primary resource for patients who are uninsured, whose insurance does not cover Prolia, or who have exhausted their insurance benefits.

Eligibility Criteria

ASNF uses household income relative to the Federal Poverty Level (FPL) as its core eligibility filter. The 2026 income ceiling is up to 500% of FPL, which translates to approximately $78,000 for a single-person household and roughly $160,000 for a family of four, based on 2025 HHS FPL figures (HHS Poverty Guidelines). Amgen reviews these thresholds annually.

Patients must also meet at least one of the following insurance criteria:

• No health insurance coverage at all
• Insurance that explicitly excludes Prolia or does not cover self-administered or physician-administered biologics
• Coverage with a deductible or coinsurance that makes the drug financially inaccessible

Documentation Required

Applicants typically submit proof of income (most recent federal tax return or two recent pay stubs), a completed patient attestation form, and a valid prescription. Prescribers sign a brief certification confirming the clinical need. All documents can be faxed to the number provided by an Amgen Assist 360 case manager or uploaded via secure portal.

How Long Does the Free-Drug Supply Last?

Approved patients receive a 12-month supply authorization, which covers two doses of Prolia. Re-enrollment is required annually. Amgen mails the prefilled syringes directly to the prescribing physician's office in temperature-controlled packaging. The patient does not handle the drug.

The HealthRX Access Decision Framework below helps prescribers route patients to the correct Amgen program at point of care:

| Patient Insurance Status | Income Threshold Met? | Recommended Program | |---|---|---| | Commercial insurance | Any income | Commercial Copay Card | | Medicare Part B or D | Any income | ASNF (if income-eligible) or State Pharmaceutical Assistance Programs | | Medicaid | Any income | Copay card ineligible; check state Medicaid coverage first | | Uninsured | Up to 500% FPL | ASNF Free Drug | | Underinsured (high deductible) | Up to 500% FPL | ASNF Free Drug | | VA / TRICARE | Any income | Copay card ineligible; use VA formulary access channels |

Medicare Patients and Prolia: Why the Copay Card Is Off-Limits

Medicare patients represent a large share of Prolia's target population, because postmenopausal osteoporosis prevalence rises sharply after age 65. Approximately 10.2 million Americans had osteoporosis in 2021 and an additional 43.3 million had low bone mass, with incidence heavily weighted toward women over 65 (CDC, National Health Statistics Reports).

Prolia is typically billed under Medicare Part B (not Part D) when administered in a physician's office, because it is a physician-administered drug under the "incident to" provision. Under Part B, patients owe a 20% coinsurance after the Part B deductible. On a $1,400 drug, that coinsurance is roughly $280 per injection or $560 per year. Medigap supplemental plans (Plans C, D, F, G, M, N) cover all or part of that 20% coinsurance, so patients with Medigap may owe nothing.

For Medicare patients without Medigap who face meaningful out-of-pocket costs, the following channels are worth exploring with a benefits counselor:

• State Pharmaceutical Assistance Programs (SPAPs): About 30 states operate SPAPs that may subsidize Part B cost-sharing for low-income Medicare beneficiaries.
• Medicare Savings Programs: Four MSP tiers (QMB, SLMB, QI, QDWI) cover Part B premiums and cost-sharing for income-qualified beneficiaries (CMS Medicare Savings Programs).
• Extra Help / Low Income Subsidy: Primarily covers Part D costs, so less directly applicable to Part B-billed Prolia, but relevant if a patient receives denosumab in another setting.

The ASNF free-drug program is technically available to Medicare patients who meet income criteria and whose coverage is deemed inadequate, but because Medicare Part B generally does cover Prolia, ASNF approval for Medicare patients is granted on a case-by-case basis and is less common than for uninsured patients.

Prior Authorization Hurdles and How Bridge Programs Address Them

Most commercial insurers and Medicare Advantage plans require prior authorization (PA) for Prolia. Common criteria include a documented bone mineral density (BMD) T-score of -2.5 or lower, or a T-score between -1.0 and -2.5 with a FRAX 10-year fracture probability exceeding 20% for major osteoporotic fracture or 3% for hip fracture, per the National Osteoporosis Foundation / American College of Rheumatology guidelines (NOF guidelines, academic.oup.com).

What Amgen Assist 360 Does During a PA Denial

Amgen Assist 360 includes a dedicated reimbursement support team that can:

• Review denial letters and identify the specific denial reason
• Prepare peer-to-peer review talking points for the prescriber
• Draft a PA appeal letter incorporating trial data from FREEDOM and the FREEDOM Extension (10-year denosumab data showing sustained fracture reduction)
• Request an expedited review when the clinical situation warrants

A 2022 analysis published in the Journal of Managed Care and Specialty Pharmacy found that manufacturer-supported PA appeal processes succeeded in reversal approximately 60% of the time across oncology and specialty biologics, compared to 35% for unaided prescriber appeals (PubMed). While that figure is not Prolia-specific, it is the best available estimate for manufacturer hub effectiveness.

Bridge Supply During PA Review

Some commercial plans take 14 to 30 days to adjudicate a PA. Because Prolia's every-6-month dosing means a delay of even several weeks can push a patient past the clinically preferred dosing window, Amgen Assist 360 may provide a short-term bridge supply of free drug during the PA review period for patients who meet basic eligibility. Prescribers should request this bridge supply proactively when submitting the PA, not after a denial is received.

Can I Use an HSA or FSA for Prolia?

Yes. Prolia is a prescription drug administered by a licensed clinician and qualifies as a medical expense under IRS Publication 502. Both Health Savings Accounts (HSAs) and Flexible Spending Accounts (FSAs) can be used to pay for Prolia's drug cost and the associated administration fee (IRS Publication 502).

Practical Coordination with the Copay Card

If a patient uses the commercial copay card and their net out-of-pocket cost is $0, there is nothing to pay with an HSA or FSA. HSA/FSA funds are most useful in two scenarios:

1. The patient is not eligible for the copay card (for example, a Medicare Advantage plan not covered by the card's terms).
2. The patient has administration fees or ancillary costs not covered by the copay card.

Patients should request an itemized receipt from their provider that clearly separates the drug charge from the administration fee, as FSA administrators may require this documentation for reimbursement.

HSA Strategic Tip

Because HSA funds roll over indefinitely, some patients choose to accumulate HSA dollars during years of lower medical spending and draw on them during the year Prolia costs are highest, such as a year in which a high deductible has not yet been met. This is a legally permissible strategy under current IRS rules.

Step-by-Step Application Guide for Patients and Prescribers

Applying to Amgen Assist 360 programs is straightforward when the process is followed in order.

For Patients Starting the Process Independently

1. Call Amgen Assist 360 at 1-888-762-6436, Monday through Friday, 8 a.m. To 8 p.m. ET.
2. Have your insurance card, a recent pay stub or tax return (for ASNF), and your prescriber's contact information ready.
3. A case manager will determine which program fits your situation and mail or email the required forms within 24 hours.
4. Return completed forms with income documentation by fax to the number provided.

For Prescriber Offices

The prescriber's office can enroll patients faster using the online portal at AmgenAssist360.com. Electronic enrollment reduces average processing time from 7 days (paper) to approximately 2 days. Several electronic health record systems, including Epic and AthenaHealth, have Amgen Assist 360 enrollment integrations built into the specialty medication workflow; check with your practice's EHR administrator.

The prescribing physician must co-sign the ASNF application attesting to the clinical necessity of denosumab and confirming that alternative therapies such as alendronate or risedronate were either tried or contraindicated. Oral bisphosphonates are first-line for most osteoporosis patients per 2022 American College of Rheumatology guidelines (ACR Guidelines, academic.oup.com), so payers and ASNF reviewers expect some documentation of why Prolia is being selected over a less expensive oral agent.

Other Ways to Reduce Prolia's Cost

Manufacturer bridge programs cover most commercially insured and uninsured patients, but several other cost-reduction channels exist for patients who fall through the gaps.

NeedyMeds and State Programs

NeedyMeds.org maintains an updated database of patient assistance programs and state-specific drug discount programs. As of early 2026, at least 12 states have included denosumab on their state pharmaceutical assistance formularies for low-income seniors.

Hospital Financial Assistance Programs

Patients who receive Prolia injections at a hospital outpatient clinic may qualify for the hospital's own charity care or financial assistance program, which operates separately from Amgen's programs. The Affordable Care Act requires non-profit hospitals to maintain financial assistance policies (IRS Form 990 Schedule H requirement, IRS.gov). A hospital social worker can submit a financial hardship application on the patient's behalf.

Switching to Biosimilars

Three FDA-approved denosumab biosimilars have received approval as of 2025: Wyost and Jubbonti (both from Sandoz), and Osenvelt (from Dr. Reddy's Laboratories). The FDA determined these products to be interchangeable with Prolia under the biosimilar interchangeability standard (FDA Biosimilar Product Information). Biosimilar denosumab list prices are running approximately 15% to 30% below Prolia's WAC in early 2026, though net prices after insurer rebates vary. Patients whose insurers require step therapy through a biosimilar first may find that biosimilar pricing, combined with any available manufacturer assistance for those products, reduces net cost below what Prolia programs offer.

The Endocrine Society's Clinical Practice Guideline on osteoporosis states: "Denosumab is appropriate for patients who cannot tolerate or have contraindications to oral bisphosphonates, or for those at very high fracture risk" (Endocrine Society Guidelines, academic.oup.com). That framing matters for PA purposes, because demonstrating bisphosphonate intolerance or contraindication is often the key to unlocking payer approval.

Avoiding the Rebound Fracture Risk When Cost Causes a Dose Gap

The single most important clinical point about cost-driven Prolia delays is the fracture rebound risk. A 2017 case series and a subsequent systematic review confirmed that patients who discontinue denosumab experience a rapid rise in bone turnover markers within 3 months, and that multiple vertebral fractures can occur in 2% to 7% of patients who stop treatment without transitioning to a bisphosphonate (PubMed, Cummings et al.). The ECTS Position Statement (2017) explicitly recommends transitioning patients to a bisphosphonate within 6 months of the last denosumab dose if discontinuation is necessary (PubMed, Tsourdi et al.).

If a bridge supply cannot be secured before a dose is overdue, the prescriber should be contacted immediately. The conversation should not wait until the next scheduled office visit.

As the Endocrine Society guideline states: "Patients who discontinue denosumab are at high risk of vertebral fracture and should be transitioned to an antiresorptive agent promptly" (academic.oup.com/jcem).

Prolia's every-6-month schedule gives most patients a built-in reminder cycle. Build the Amgen Assist 360 re-enrollment into that cycle: submit re-enrollment paperwork 60 days before the next dose is due, not after the appointment is already scheduled.